On May 22, 2014, Generex Biotechnology Corporation (the "Company") held its
Annual Meeting at 201 Bridgeland Avenue, Toronto, Ontario, M6A 1Y7. The
following proposals were submitted to the stockholders at the Annual Meeting:

1. To elect five directors;

2. To ratify the appointment of MNP LLP as independent public accountants for
the year ending July 31, 2014;

3. To approve an amendment to our Restated Certificate of Incorporation to
effect, at any time prior to December 31, 2015, a reverse stock split of
our common stock at an exchange ratio to be determined and to
proportionately reduce the number of shares of the common stock authorized
for issuance (the implementation of the reverse stock split, ratio and
timing of which will be subject to the discretion of the Board of
Directors) (the "Reverse Stock Split Proposal");

4. To approve the adjournment of the annual meeting, if necessary, to solicit
additional proxies to vote in favor of the proposal set forth in Item 3
(the "Adjournment Proposal");

5. To approve an amendment to the Generex Biotechnology Corporation 2006
Stock Plan and to approve the 2006 Stock Plan, as amended; and

6. To conduct any other business as may properly come before the annual
meeting or any adjournment or postponement thereof.

Only stockholders of record as of the close of business on March 31, 2014 were
entitled to vote at the Annual Meeting. As of March 31, 2014, 735,000,473 shares
of common stock of the Company were outstanding and entitled to vote at the
Annual Meeting. At the Annual Meeting, 528,551,909 shares of common stock of the
Company were represented, in person or by proxy, constituting a quorum.

The votes with respect to the proposals are set forth below.

(1) Elect the Directors of the Company to serve until the 2015 Annual Meeting:

The following nominees were elected as directors to serve until the 2015 Annual
Meeting by the votes indicated below:

(2) Ratification of the appointment of MNP LLP as the Company's independent
registered public accounting firm for the fiscal year ending July 31, 2014:

The proposal to ratify the appointment of MNP LLP as the Company's independent
registered public accountant for fiscal year ending July 31, 2014 was approved
by the votes indicated below. There were no broker non-votes on this proposal.

FOR AGAINST ABSTAIN

493,437,921 26,068,281 9,045,707

(3) Reverse Stock Split Proposal:

The Reverse Stock Split Proposal was approved as 53.74% of the outstanding
common stock voted in favor of the Reverse Stock Split Proposal and a vote of at
least 50% of the outstanding common stock in favor of the proposal was required
to approve it. There were no broker non-votes on this proposal.

FOR AGAINST ABSTAIN

395,027,850 130,289,468 3,234,591

(4) Proposal to approve an adjournment if necessary:

The Adjournment Proposal was approved.

FOR AGAINST ABSTAIN

392,381,049 126,962,668 9,208,192

(5) Proposal to approve an amendment to the Generex Biotechnology Corporation
2006 Stock Plan and to approve the 2006 Stock Plan, as amended:

The proposal to approve an amendment to the Generex Biotechnology Corporation
2006 Stock Plan and to approve the 2006 Stock Plan, as amended; was approved.